Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.
Epidemiologic studies suggest that type 2 diabetes (T2D) increases breast cancer risk and mortality, but there is limited experimental evidence supporting this association. Moreover, there has not been any definition of a pathophysiological pathway that diabetes may use to promote tumorigenesis. In the present study, we used the MKR mouse model of T2D to investigate molecular mechanisms that link T2D to breast cancer development and progression. MKR mice harbor a transgene encoding a dominant-negative, kinase-dead human insulin-like growth factor-I receptor (IGF-IR) that is expressed exclusively in skeletal muscle, where it acts to inactivate endogenous insulin receptor (IR) and IGF-IR. Although lean female MKR mice are insulin resistant and glucose intolerant, displaying accelerated mammary gland development and enhanced phosphorylation of IR/IGF-IR and Akt in mammary tissue, in the context of three different mouse models of breast cancer, these metabolic abnormalities were found to accelerate the development of hyperplastic precancerous lesions. Normal or malignant mammary tissue isolated from these mice exhibited increased phosphorylation of IR/IGF-IR and Akt, whereas extracellular signal-regulated kinase 1/2 phosphorylation was largely unaffected. Tumor-promoting effects of T2D in the models were reversed by pharmacological blockade of IR/IGF-IR signaling by the small-molecule tyrosine kinase inhibitor BMS-536924. Our findings offer compelling experimental evidence that T2D accelerates mammary gland development and carcinogenesis,and that the IR and/or the IGF-IR are major mediators of these effects.
Novosyadlyy
Ruslan
R
Division of Endocrinology, Diabetes and Bone Diseases, The Samuel Bronfman Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA.
Lann
Danielle E
DE
Vijayakumar
Archana
A
Rowzee
Anne
A
Lazzarino
Deborah A
DA
Fierz
Yvonne
Y
Carboni
Joan M
JM
Gottardis
Marco M
MM
Pennisi
Patricia A
PA
Molinolo
Alfredo A
AA
Kurshan
Naamit
N
Mejia
Wilson
W
Santopietro
Stefania
S
Yakar
Shoshana
S
Wood
Teresa L
TL
LeRoith
Derek
D
D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D005260:Female; D006946:Hyperinsulinism / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D007328:Insulin / Q000097:blood; D008321:Mammary Glands, Animal / Q000254:growth & development / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000097:blood / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D051058:Oncogene Protein v-akt / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010766:Phosphorylation; D011728:Pyridones / Q000494:pharmacology; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D011972:Receptor, Insulin / Q000037:antagonists & inhibitors / Q000378:metabolism
C504983:BMS 536924; D001562:Benzimidazoles; D007328:Insulin; D011728:Pyridones; D019869:Phosphatidylinositol 3-Kinases; D017526:Receptor, IGF Type 1; D011972:Receptor, Insulin; D051058:Oncogene Protein v-akt